[18F]F-胆碱PET/CT与传统影像对中高危前列腺癌分期的前瞻性随机多中心研究
这项在7个意大利中心开展的前瞻性随机III期试验,将256例中高危前列腺癌患者按1:1随机分组,比较传统影像(腹盆腔增强CT加骨扫描)与加做[18F]F-胆碱PET/CT的分期效果。PET/CT组淋巴结转移灵敏度高于对照组,[18F]F-胆碱耐受良好,PET/CT使不必要的扩大淋巴结清扫约减少8%,对5年总生存率有4%的提升。结论认为[18F]F-胆碱PET/CT诊断性能优于传统影像,支持考虑停止用传统影像进行前列腺癌分期。
要点
- [18F]F-胆碱PET/CT组淋巴结转移灵敏度高于传统影像组(77.78% vs 28.57%;65.62% vs 17.65%)。
- [18F]F-胆碱耐受良好,PET/CT使不必要的扩大淋巴结清扫较增强CT约减少8%。
- PET/CT对5年总生存率有边缘性影响,贡献4%的生存率提升。
核心结论
- 在中高危前列腺癌初始分期中,[18F]F-胆碱PET/CT检测转移的诊断性能优于传统影像。
- [18F]F-胆碱PET/CT使不必要的扩大淋巴结清扫率最多降低8%。
- 这些发现支持考虑停止用传统影像进行前列腺癌分期。
研究设计与样本
- 前瞻性对照、开放、随机、多中心III期试验,涉及7个意大利中心。
- 符合条件的中高危前列腺癌患者按1:1比例随机分组。
- 一组接受传统影像(腹盆腔增强CT和骨扫描),另一组接受传统影像加[18F]F-胆碱PET/CT。
- 研究提前终止,但所有终点均经过充分分析和充实。
- 2016年2月至2020年12月间共随机分配256例患者,最终评估236例(对照组117例,试验组119例)。
主要发现
- 试验组淋巴结转移灵敏度高于对照组(77.78% vs 28.57%及65.62% vs 17.65%),由最终病理和系列前列腺特异性抗原评估确定。
- [18F]F-胆碱耐受良好。
- 与传统增强CT相比,使用[18F]F-胆碱PET/CT使不必要的扩大淋巴结清扫约减少8%。
- [18F]F-胆碱PET/CT对5年总生存率有边缘性影响,贡献4%的生存率提升。
临床怎么用
- 作者结论认为,这些发现支持考虑停止用传统影像进行前列腺癌分期。
局限性
- 研究提前终止。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This study aimed to compare the efficacy of [18F]F-choline PET/CT with conventional imaging for staging and managing intermediate- to high-risk prostate cancer (PCa). The primary objective was to assess the ability of PET/CT with [18F]F-choline to identify lymph node and systemic involvement during initial staging. Secondary objectives included evaluating the impact of [18F]F-choline PET/CT on unnecessary local treatments and assessing the safety of [18F]F-choline agents. Additionally, the study aimed to analyze recurrence-free survival and overall survival 5 y after randomization. Methods: A prospective controlled, open, randomized multicenter phase III trial involving 7 Italian centers was conducted. Eligible patients with intermediate- to high-risk PCa were randomized in a 1:1 ratio. Two groups were formed: one undergoing conventional imaging (abdominopelvic contrast-enhanced CT and bone scanning) and the other receiving conventional imaging plus [18F]F-choline PET/CT. The study was terminated prematurely; however, all the endpoints were thoroughly analyzed and enriched. Results: Between February 2016 and December 2020, 256 patients were randomly assigned. In total, 236 patients (117 in the control arm and 119 in the experimental arm) were considered for the final assessment. In the experimental arm, the sensitivity for lymph node metastases, determined by final pathology and serial prostate-specific antigen evaluations, was higher than in the control arm (77.78% vs. 28.57% and 65.62% vs. 17.65%, respectively). The [18F]F-choline was tolerated well. The use of [18F]F-choline PET/CT resulted in an approximately 8% reduction in unnecessary extended lymphadenectomy compared with contrast-enhanced CT. Additionally, [18F]F-choline PET/CT had a marginal impact on 5-y overall survival, contributing to a 4% increase in survival rates. Conclusion: In the initial staging of PCa, [18F]F-choline PET/CT exhibited diagnostic performance superior to that of conventional imaging for detecting metastases. [18F]F-choline PET/CT reduced the rate of unnecessary extensive lymphadenectomy by up to 8%. These findings support the consideration of discontinuing conventional imaging for staging PCa.
引用
- Evangelista L, Zattoni F, Burei M, et al. A Prospective Randomized Multicenter Study on the Impact of [18F]F-Choline PET/CT Versus Conventional Imaging for Staging Intermediate- to High-Risk Prostate Cancer. J Nucl Med. 2024. PMID: 38844361. doi:10.2967/jnumed.123.267355
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。